|
|
Vol. 15.18 – 26 July, 2024
|
|
|
|
|
|
|
|
Researchers determined if Stockholm3 could improve prostate cancer detection in a diverse cohort. An observational prospective multicentered clinical trial, supplemented by prospectively recruited participants in a urology clinic setting included men with suspicion of prostate cancer and underwent prostate biopsy. [Journal of Clinical Oncology]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
While Notch could be oncogenic in early prostate cancer, scientists identified significant downregulation of the Notch pathway during prostate cancer progression from adenocarcinoma to neuroendocrine prostate cancer where it functioned as a tumor suppressor.
[Journal of Clinical Investigation]
|
|
|
|
|
|
Investigators found that the deubiquitinase USP11 targeted both androgen receptor and c-Myc in prostate cancer (PCa). USP11 expression was up-regulated in metastatic PCa and castration-resistant prostate cancer.
[Proceedings of The National Academy of Sciences of The United States of America]
|
|
|
|
|
|
Through the suppression of branched-chain amino acid (BCAA) availability, researchers reported significantly reduced lipid content, strongly indicating that BCAAs were important lipogenic fuels in prostate cancer.
[Cell Death & Disease]
|
|
|
|
|
|
The authors showed that the less studied member of the Immediate Early Response (IER) family, IER 5 like (IER5L), was upregulated in aggressive prostate cancer.
[Cell Death & Disease]
|
|
|
|
|
|
Researchers demonstrated that protein restriction without calorie restriction did not reduce serum IGF-1 concentration or increase IGFBP-1 and IGFBP-3 in men with localized prostate cancer.
[Biomarker Research]
|
|
|
|
|
|
Investigators utilized the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort clinical-genomic database for this retrospective analysis. [Prostate Cancer and Prostatic Diseases]
|
|
|
|
|
|
|
|
Given the need for novel approaches to treat PCa (prostate cancer), there is significant interest in new therapies that target m6A that modulate androgen receptor expression and androgen signaling. This review critically summarizes the potential benefit of such epitranscriptomic therapies for PCa patients. [Neoplasia]
|
|
|
|
|
|
|
|
Blue Earth Therapeutics announced a clinical research collaboration with University College London (UCL) to evaluate the safety, tolerability, radiation dosimetry, and anti-tumor activity of the company’s 225Ac-rhPSMA-10.1 in men with metastatic castrate-resistant prostate cancer. [Blue Earth Therapeutics]
|
|
|
|
|
|
|
|
August 19 – 21, 2024 San Diego, California, United States
|
|
|
|
|
|
|
|
|
|
|
Pfizer – York New Salem, Pennsylvania, United States
|
|
|
|
|
|
|
University of Algarve – Faro, Portugal
|
|
|
|
|
|
|
National Cancer Institute – Bethesda, Maryland, United States
|
|
|
|
|
|
|
Goethe University Frankfurt am Main – Frankfurt, Germany
|
|
|
|
|
|
|
KU Leuven – Leuven, Belgium
|
|
|
|
|
|